Ameliora Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Ameliora Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.7K	Sell	700 -300	-30%	-$9.99K	0.01%	173
2026 Q1	$30.1K	Sell	1,000 -2,000	-67%	-$64.3K	0.01%	168
2025 Q4	$93.6K	Hold	3,000	–	–	0.03%	133
2025 Q3	$60.6K	Hold	3,000	–	–	0.02%	143
2025 Q2	$50.3K	Hold	3,000	–	–	0.02%	150
2025 Q1	$46.1K	Hold	3,000	–	–	0.02%	158
2024 Q4	$66.1K	Buy	+3,000	New	+$54.6K	0.02%	147

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Ameliora Wealth Management's TEVA Position: Q2 2026 in Review

Ameliora Wealth Management reduced its Teva Pharmaceuticals (TEVA) stake by 30% in Q2 2026, selling an estimated $9.99K and leaving 700 shares worth $23.7K. The position accounts for 0.01% of the portfolio, ranked #173.

Ameliora Wealth Management first reported a position in TEVA in Q4 2024 and has held it in 7 quarters since. The position peaked at $93.6K in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Ameliora Wealth Management held 700 shares of Teva Pharmaceuticals worth $23.7K as of Q2 2026.
Ameliora Wealth Management sold 300 Teva Pharmaceuticals shares in Q2 2026, an estimated $9.99K.
Teva Pharmaceuticals made up 0.01% of Ameliora Wealth Management's portfolio in Q2 2026, its #173 holding.
Ameliora Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Ameliora Wealth Management's Teva Pharmaceuticals position peaked at $93.6K in Q4 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Ameliora Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.